Maraviroc "LOWERS" PDL1
But i dont feel like looking up the actual study.
(I lied, here it is maybe?, its been a while since I saw it):
Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial
https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.3010
The study is searchable and OHM knows about it.
It dont prime.
"Yes, studies indicate that maraviroc can lower PD-L1 (Programmed Death-Ligand 1) expression and inhibit PD-L1-mediated immune evasion in certain cancer models.
Here is a breakdown of the evidence regarding maraviroc and PD-L1:
Mechanism in Cancer: Cancer-associated fibroblasts (CAFs) secrete CCL5, which binds to the CCR5 receptor on cancer cells. This interaction triggers a signaling pathway (AKT) that upregulates both the androgen receptor (AR) and PD-L1.
Effect of Maraviroc: As a CCR5 antagonist, maraviroc blocks this CCL5-CCR5 signaling pathway, thereby reducing the expression of PD-L1 and improving the effectiveness of other treatments (e.g., enzalutamide)"